Aseptic Fill Finish for Complex Drug Products

Drugs conveyed through otic, ophthalmic, and parenteral routes have high risks of harm or infection. This is because they diverse many of the natural defenses in the body. To make sure patients are safe, the Food and Drug Administration demands that drug products conveyed through these paths be provided as sterile products. 

This induction includes a lot of complex drug products, which include sterile injectables, ophthalmic suspension, aqueous-based aerosols (for inhalation), and lyophilized powders (injections)

Our article talks about sterile lyophilization of drug products. To learn more about this, scroll down and keep reading. 

Sterile Lyophilization of Duct Drug Products

As big molecule formulations and drug products become popular, a large number of pharmaceutical formulations have challenges with solution stability and when this happens, there is impossibility of ready-to-use liquid dosage. 

To fix this challenge, a lot of parenteral products pass through lyophilization to produce a stable powder for transport and storage.  

The Process of Lyophilization

If a drug product needs lyophilization, flakes of solutions are moderately stoppered during sterile fill-finish and are packed into trays that would be moved to the lyophilizer. 

Solutions undergo three steps once they have been transferred to the lyophilizer.

Step 1: Freezing: the solution’s temperature is reduced at a predetermined level to make sure there is total freezing and a beneficial crystal structure in the solid that has been frozen.

Step 2: Primary Drying: This is done to encourage drying through sublimation. There is a gradual reduction of the pressure that is inside the drying chamber. 

Step 3: Secondary Drying: The drying chamber’s temperature is gradually increased under low pressure. This is done to get rid of any remaining solvent that is still bound to the material chemically. 

At the end of the third step, the flakes (vials) are completely stoppered to reduce further subjection to the environment. 

Lyophilization is a beneficial and accepted technology. However, like most things, it comes with some challenges. Here are some of the challenges that come with lyophilization:

1. High Risk of Additional Contamination

Lyophilization in fill-finish manufacturing, there is a high risk of additional contamination. This mostly occurs during the loading of the partly stoppered vial. It leaves drug products exposed to the outside environment, and this raises the risk of contamination. 

Thus, all of the activities related to lyophilization must be carried out in a Critical Area. There must be extensive monitoring and validation of cleaning procedures during this operation. 

2. It Requires Specialized Knowledge 

Lyophilization in drug fill-finish, a vast understanding of sublimation, and freezing processes are required in lyophilization and scale-up. Factors like phase transition temperature, heat transfer via vials, and the changes that occur in the crystal structure, must be fully understood. 

3. Requires High Capital Investment

The development of a lyophilization cycle in aseptic fill-finish can require pilot-scale equipment in portable batches.  But in large-scale size, millions of dollars are needed for installation and maintenance. 

At AbbVie, the nature of your biologic drug notwithstanding, you can count on us when it comes to aseptic fill-finish manufacturing. We will provide reliable, safe, and ready to use products. To learn more about how we can assist you with aseptic fill-finish, feel free to contact us and reach out to us; we shall be more than pleased to support you.